India Pharma Outlook Team | Monday, 21 July 2025
Top-line findings from two Phase 3 clinical trials assessing the safety and effectiveness of tildrakizumab 100 mg (ILUMYA) given over a 24-week period for the treatment of active psoriatic arthritis were released today by Sun Pharmaceutical Industries Limited.
At Week 24, tildrakizumab 100 mg (ILUMYA) medication led to more improvements in PsA signs and symptoms than placebo treatment. With a greater percentage of patients treated with tildrakizumab attaining ACR20 responses at week 24 than those getting a placebo (p < 0.05), both the INSPIRE-1 and INSPIRE-2 investigations met the primary goal.
"We are excited to share that both the INSPIRE-1 and INSPIRE-2 clinical trials have successfully met their primary endpoints. These top-line results reinforce the therapeutic potential of ILUMYA as a treatment option for patients with active psoriatic arthritis. We extend our sincere gratitude to the patients, healthcare professionals and administrators whose contributions made the studies possible. We look forward to sharing the complete clinical data in the near future,” said Marek Honczarenko, MD, PhD, Senior Vice President and Head of Global Specialty Development at Sun Pharma.
Also Read: New Agilent Pro iQ Series Enhances LC-MS Detection in India
The studies' safety data aligned with ILUMYA's established safety profile. ILUMYA is authorized to treat individuals with moderate-to-severe plaque psoriasis who may benefit from systemic medication or phototherapy. The INSPIRE-1 and INSPIRE-2 studies did not find any new safety signals.
